| Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma (NCT03480087) | A.O.U. Città della Salute e della Scienza | 2015-01-01 |
| Molecular and Whole-body MR Imaging in Lymphomas (NCT02389101) | Turku University Hospital | 2014-10-01 |
| Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (NCT02098109) | Washington University School of Medicine | 2014-08-20 |
| B-Cell Hematologic Malignancy Vaccination Registry (NCT02298816) | Wake Forest University Health Sciences | 2014-08-01 |
| Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant (NCT03301168) | Bellicum Pharmaceuticals | 2014-04-01 |
| Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (NCT01996865) | Celgene | 2014-04-01 |
| Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (NCT01969435) | Washington University School of Medicine | 2014-03-19 |
| Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) (NCT02038933) | Bristol-Myers Squibb | 2014-03-05 |
| A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (NCT01992653) | Genentech, Inc. | 2013-11-29 |
| Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (NCT01938001) | Celgene | 2013-11-21 |
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (NCT02055820) | Hoffmann-La Roche | 2013-11-17 |
| Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL (NCT01754857) | University of Wisconsin, Madison | 2013-11-12 |
| Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim (NCT03057418) | Biointegrator LLC | 2013-06-01 |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine (NCT01866839) | National Heart, Lung, and Blood Institute (NHLBI) | 2013-05-29 |
| Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NCT01660451) | Bayer | 2012-11-19 |
| Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (NCT01720264) | Sherif S. Farag | 2012-11-02 |
| Tissue Collection for Studies of Lymph Cancer (NCT01676805) | National Cancer Institute (NCI) | 2012-09-21 |
| Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) (NCT01745354) | Robert Lowsky | 2012-08-01 |
| Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma (NCT01555853) | Washington University School of Medicine | 2012-07-01 |
| Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NCT02072967) | Astellas Pharma Europe B.V. | 2012-05-01 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NCT01534715) | ImmunoGen, Inc. | 2012-01-01 |
| Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP (NCT01843868) | Australasian Leukaemia and Lymphoma Group | 2012-01-01 |
| BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (NCT01403948) | Boehringer Ingelheim | 2011-08-01 |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01421667) | Seagen Inc. | 2011-08-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas (NCT01263418) | UNC Lineberger Comprehensive Cancer Center | 2011-06-01 |
| Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) (NCT01294579) | Novartis Pharmaceuticals | 2011-05-17 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (NCT01186458) | Hoosier Cancer Research Network | 2010-10-01 |
| Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (NCT00871702) | Washington University School of Medicine | 2010-10-01 |
| Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease (NCT01155817) | Stanford University | 2010-08-01 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients (NCT01121120) | Tarix Pharmaceuticals | 2010-06-01 |
| Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) (NCT01196520) | National Cancer Institute (NCI) | 2010-05-25 |
| An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study (NCT01090414) | Gilead Sciences | 2010-03-22 |
| Cardiac Safety Study of Brentuximab Vedotin (SGN-35) (NCT01026233) | Seagen Inc. | 2010-01-01 |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) (NCT01026415) | Seagen Inc. | 2009-12-01 |
| A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma (NCT01015911) | Seagen Inc. | 2009-11-01 |
| Pilot Study of Unrelated Cord Blood Transplantation (NCT00916045) | King's College Hospital NHS Trust | 2009-09-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit (NCT01050946) | Medical College of Wisconsin | 2009-07-01 |
| A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study (NCT00947856) | Seagen Inc. | 2009-07-01 |
| Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (NCT00882895) | Washington University School of Medicine | 2009-05-05 |
| Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma (NCT00901069) | Shams Shakil | 2009-05-01 |
| Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma (NCT00896493) | Stanford University | 2009-05-01 |
| Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) (NCT00912223) | Medical College of Wisconsin | 2009-04-01 |
| Sitagliptin Umbilical Cord Blood Transplant Study (NCT00862719) | Indiana University | 2009-03-01 |
| A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma (NCT00866047) | Seagen Inc. | 2009-03-01 |
| A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas (NCT00880581) | Ronald Levy | 2009-01-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma (NCT00733824) | Washington University School of Medicine | 2008-11-01 |
| A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) (NCT00779584) | Merck Sharp & Dohme LLC | 2008-10-17 |
| Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma (NCT00903890) | University of Rochester | 2008-08-01 |
| Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma (NCT00724984) | Pharmacyclics LLC. | 2008-07-01 |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL (NCT00655837) | Seagen Inc. | 2008-04-01 |
| Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma (NCT00644124) | Sanofi | 2008-03-01 |
| A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies (NCT00649584) | Seagen Inc. | 2008-03-01 |
| Functional Assessment of Cancer Therapy - Bone Marrow Transplant (NCT01490957) | King Faisal Specialist Hospital & Research Center | 2008-03-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas (NCT00572637) | Ethical Oncology Science | 2007-11-01 |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients (NCT00562224) | Pharmacyclics LLC. | 2007-11-01 |
| T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE (NCT00578461) | Baylor College of Medicine | 2007-10-01 |
| High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas (NCT01148173) | Charite University, Berlin, Germany | 2007-10-01 |
| Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT (NCT00534989) | King Faisal Specialist Hospital & Research Center | 2007-09-01 |
| A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma (NCT00538096) | MedImmune LLC | 2007-09-01 |
| A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL (NCT00529503) | Seagen Inc. | 2007-09-01 |
| Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma (NCT00536835) | GlaxoSmithKline | 2007-08-16 |
| A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (NCT00500058) | GlaxoSmithKline | 2007-07-31 |
| Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis (NCT00553943) | Lymphoma Study Association | 2007-07-01 |
| Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases (NCT00538551) | King Faisal Specialist Hospital & Research Center | 2007-01-01 |
| Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy (NCT00490490) | Stanford University | 2007-01-01 |
| Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma (NCT00481832) | Stanford University | 2007-01-01 |
| Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) (NCT00426855) | Peter Moosmann | 2007-01-01 |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NCT00435916) | Seagen Inc. | 2006-12-01 |
| CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma (NCT00455897) | Massachusetts General Hospital | 2006-12-01 |
| Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies (NCT00430846) | Seagen Inc. | 2006-11-01 |
| VELCADE,Rituximab,Cyclophosphamide and Decadron (NCT00413959) | Oncology Specialists, S.C. | 2006-08-01 |
| Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (NCT00324467) | British Columbia Cancer Agency | 2006-08-01 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (NCT00871663) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT (NCT00350181) | Stanford University | 2006-08-01 |
| Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma (NCT00347971) | ZymoGenetics | 2006-06-01 |
| A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. (NCT00333008) | The Alvin and Lois Lapidus Cancer Institute | 2006-05-01 |
| Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (NCT00368082) | Baylor College of Medicine | 2006-04-01 |
| Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) (NCT00329030) | National Heart, Lung, and Blood Institute (NHLBI) | 2005-12-01 |
| A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen (NCT00319332) | GlaxoSmithKline | 2005-09-01 |
| Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) (NCT00156013) | Oncology Specialists, S.C. | 2005-09-01 |
| Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. (NCT00354822) | A.O. Ospedale Papa Giovanni XXIII | 2005-08-01 |
| Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma (NCT00367497) | Keio University | 2005-08-01 |
| Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma (NCT00188929) | University Health Network, Toronto | 2005-08-01 |
| A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease (NCT00412321) | Centocor, Inc. | 2005-05-01 |
| Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma (NCT00185731) | Dean Felsher | 2005-04-01 |
| AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF (NCT00396266) | Genzyme, a Sanofi Company | 2005-01-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients (NCT00103610) | Genzyme, a Sanofi Company | 2005-01-01 |
| A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer (NCT00147485) | Pfizer | 2004-12-01 |
| Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma (NCT00268983) | GlaxoSmithKline | 2004-10-01 |
| Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322842) | Genzyme, a Sanofi Company | 2004-09-01 |
| A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer (NCT00141297) | Pfizer | 2004-09-01 |
| BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) (NCT00088530) | CTI BioPharma | 2004-07-01 |
| Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (NCT00094848) | Human Genome Sciences Inc. | 2004-06-01 |